B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2027

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of proliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. B-cell lymphomas comprise approximately 85% of all NHL cases diagnosed in the US, and are a diverse group of blood cancers that arise in the B-cells. This report focuses on the four NHL subtypes that represent the greatest commercial opportunities for drug developers during the forecast period: Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal zone lymphoma (MZL) and Mantle cell lymphoma (MCL).
The introduction of Roche’s Rituxan/MabThera (rituximab) in the late 1990s revolutionized NHL therapy, and the market is now dominated by Rituxan. However, NHL patients frequently become refractory to Rituxan therapy or relapse after responding to the first-line treatment, which has spurred R&D efforts to address therapeutic options for relapsed/refractory (R/R) patients after first-line Rituxan-based therapy.
GlobalData valued the B-cell NHL (FL,MZL,DLBCL and MCL) market at $5.7B in 2017 in the 7MM (US, France, Germany, Italy, Spain, UK and Japan) and expects the market to increase to $9.2B in 2027 at a Compound Annual Growth Rate (CAGR) of 4.9%. Growth will be driven by the rise of chimeric antigen receptor (CAR)-T cell therapies, the launch of six pipeline agents, and the label expansion of currently marketed therapies across the B-cell NHL subtypes. However, growth will be tempered by the biosimilar and generic erosions of Rituxan, Treanda, Gazyva, Revlimid, Imbruvica, Zydelig, Velcade, and Torisel.
Key Questions Answered
Which pipeline agents are the most promising and expected to launch in the 7MM? What are the forecasted sales of these agents and what will be their impact in the B-cell NHL market?
What are the main unmet needs in B-cell NHL , which pipeline drugs will fulfill these needs, and to what extent?
What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
Key Opinions Leaders (KOLs) insights across the 7MM, relating to the current treatment options and opinions on the late and early stage pipeline agents.

Scope

Overview of B-cell NHL (FL, MZL, DLBCL and MCL), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized CLL therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven geographic regions, forecast from 2017 to 2027. Forecast model includes previously diagnosed and newly diagnosed patients.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the B-cell NHL therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for B-cell NHL . The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global B-cell NHL market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Growth will be driven by the rise of CAR-T cell therapies, the launch of six pipeline agents, and the label expansion of currently marketed therapies across the B-cell NHL subtypes.

Lisocabtagene maraleucel, ublituximab + umbralisib and Polivy are the three pipeline/upcoming therapies expected to generate the highest sales for B-cell NHL from 2017-2027.

Several unmet needs still remain in B-cell NHL, and while it is unlikely that they will be fully met within the forecast period, progress will be made on many of those needs.

The growth of the B-cell NHL market will be tempered by the patent expiry of leading brands, including Rituxan, Treanda, Gazyva, Revlimid, Imbruvica, Zydelig, and Velcade, and subsequent biosimilar/generic erosion

Lack of, or delayed, clinical development in Japan, will result in marketing approval of only a subset of the pipeline candidates in that region during the forecast period

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global B-cell NHL market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global B-cell NHL market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.